121 related articles for article (PubMed ID: 9612066)
1. [Development of HIV protease inhibitors as anti AIDS drugs: molecular design based on substrate transition state].
Kiso Y
Tanpakushitsu Kakusan Koso; 1998 May; 43(6):725-33. PubMed ID: 9612066
[No Abstract] [Full Text] [Related]
2. Development of HIV protease inhibitors: a survey.
Ren S; Lien EJ
Prog Drug Res; 1998; 51():1-31. PubMed ID: 9949858
[TBL] [Abstract][Full Text] [Related]
3. Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.
Lallemand F; Adda N; Schneider V; Jacomet C; Salhi Y; Rozenbaum W
Clin Infect Dis; 1999 May; 28(5):1184-5. PubMed ID: 10452672
[No Abstract] [Full Text] [Related]
4. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
5. [HIV protease inhibitors].
Rubio R; Romeu J; Viciana P; Redondo C
Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():10-4. PubMed ID: 9053020
[No Abstract] [Full Text] [Related]
6. [Clinical application of HIV protease inhibitors].
Chiba N; Shintani M; Ueno T; Hayashi H
Tanpakushitsu Kakusan Koso; 1998 May; 43(6):744-51. PubMed ID: 9612068
[No Abstract] [Full Text] [Related]
7. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
8. A patient's guide to protease inhibitors.
Elperin A; Sax P
AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
[TBL] [Abstract][Full Text] [Related]
9. Viramune cleared for use in combination with protease inhibitors.
AIDS Patient Care STDS; 1998 Nov; 12(11):872. PubMed ID: 11362046
[No Abstract] [Full Text] [Related]
10. Update on HIV protease inhibitors.
Vella S
AIDS Clin Care; 1995 Oct; 7(10):79-82, 88. PubMed ID: 11362832
[TBL] [Abstract][Full Text] [Related]
11. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
12. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].
Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin MA; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux JM; Calvez V
Pathol Biol (Paris); 1999 May; 47(5):549-52. PubMed ID: 10418038
[TBL] [Abstract][Full Text] [Related]
13. [Protease inhibitors--a class of substances ready to take off].
Keysser G; Burmester GR
Dtsch Med Wochenschr; 1997 Jun; 122(25-26):805-7. PubMed ID: 9244667
[No Abstract] [Full Text] [Related]
14. What they say about protease inhibitors.
Posit Aware; 1999; 10(1):38-43. PubMed ID: 11366522
[TBL] [Abstract][Full Text] [Related]
15. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
Lepsík M; Kríz Z; Havlas Z
Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
[TBL] [Abstract][Full Text] [Related]
16. Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.
Stoffler D; Sanner MF; Morris GM; Olson AJ; Goodsell DS
Proteins; 2002 Jul; 48(1):63-74. PubMed ID: 12012338
[TBL] [Abstract][Full Text] [Related]
17. [Screening of new HIV inhibitors based on the database of traditional Chinese medicine].
Gao WN; Li Y; Zhang R; Gao H; Xu WR; Li AX; Du QS; Zhang X; Wei DQ
Yao Xue Xue Bao; 2006 Mar; 41(3):241-6. PubMed ID: 16758996
[TBL] [Abstract][Full Text] [Related]
18. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
[TBL] [Abstract][Full Text] [Related]
19. Hyperlipidemia associated with the use of protease inhibitors.
Smith JH; Martin GJ; Decker CF
Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
[No Abstract] [Full Text] [Related]
20. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
Lu D; Sham YY; Vince R
Bioorg Med Chem; 2010 Mar; 18(5):2037-48. PubMed ID: 20138769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
